November 16, 2016
Across the United States, the high cost of hepatitis C (HCV) drugs means that patients often struggle to access life-saving treatment. State-level Medicaid programs are legally obligated to provide these drugs, but many programs find ways to deny treatment. The three more common tactics employed are liver damage (fibrosis) restrictions, prescriber restrictions and sobriety restrictions.
While restrictions vary state by state, restrictions eased somewhat across the country from 2014 to 2016, according to preliminary data presented at the Liver Meeting 2016, by Robert Greenwald, director, Center for Health Law and Policy Innovation at Harvard Law School, and Ryan Clary, executive director of the National Viral Hepatitis Roundtable. Greenwald presented the 2016 data as an update to his 2014 survey of state Medicaid policies.
Credit: zimmytws for iStock via Thinkstock.
Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|CDC Corrects Misleading HIV Conception Guidance, Responding to Community Pressure|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|
|New York Study Finds Almost Half of HIV-Positive Gay Men Co-Infected With Hepatitis C Have Detectable Levels of Hepatitis C Virus in Their Rectal Fluid|
|This Week in HIV Research: A New Glimpse Into HAND|
|This Week in HIV Research: New Discovery in How HIV Hijacks a Cell|
|Research in New York Confirms That MSM Will Likely Follow Up After a Positive at-Home HIV Test|